3649 results for «684»
3649 results
TAVI and aortic valve procedures
11 Oct 2025 – From AICT-AsiaPCR 2025
Focusing on transcatheter aortic valve interventions, this session covers a broad spectrum of complex cases including emergent TAV-in-SAV procedures, management of severely calcified bicuspid valves, zero-contrast TAVI techniques, and strategies for hostile anatomies. It provides valuable insights into procedural planning and follow-up to optimize patient care...
Valve-in-valve in degenerated surgical bioprothesis mitral valve - LIVE Case
10 Oct 2025 – From AICT-AsiaPCR 2025
A 78-year-old male with a history of rheumatic disease underwent surgical mitral valve replacement (Perimount Magna 25), surgical aortic valve replacement (Perimount Magna), and CABG (LIMA–LAD) in 2010. He presented with symptomatic severe mitral regurgitation and normal LV function.
He was treated with implantation of a 26...
IVUS or OCT? Choosing the right imaging for the right lesion - A case-based debate
10 Oct 2025 – From AICT-AsiaPCR 2025
This case-based debate examines the complementary roles of IVUS and OCT imaging modalities in precision PCI. It highlights lesion-specific factors guiding modality choice, including left main disease, bifurcations, calcified plaques, and acute coronary syndromes, supported by real-world clinical cases demonstrating imaging-based decision-making.
EuroPCR 2018 Opening Ceremony and Ethica Awards
22 May 2018 – From EuroPCR 2018
Join J. Fajadet and W. Wijns for the EuroPCR 2018 Opening Ceremony and find out who this year's Ethica Awards winners are!
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
